The General Hospital Corporation

Other

American National Red Cross

Robert D Moir

Rudolph Emile Tanzi

Ashley I Bush

Bradley T Hyman

Maria Z Kounnas

Dudley K Strickland

G William Rebeck

The invention relates to antibodies that bind cross-linked amyloid &#x3b2; oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.

Methods of diagnosing alzheimer's disease by detecting antibodies to cross-linked &#x3b2;-amyloid oligomers

The disclosed invention relates to assays for detecting and quantifying A&#x3b2; peptide, using solid supports that are coated with heavy metal cations, such as zinc (II) or copper (II) form of a nitriloacetic acid. Further, diagnostic kits are described which are used to carry out the assays of the present invention. An improvement in an assay for detection of A&#x3b2; peptide is suggested which comprises forming a heavy metal cation/solid support complex. The preferred heavy metal cations for this improvement are zinc (II) or copper (II) form of a nitriloacetic acid. Finally, methods and kits for bulk purification of A&#x3b2; peptides from biological fluids are taught.

Diagnostic assay for Alzheimer's disease: assessment of A&#x3b2; abnormalities

The present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid &bgr;-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Modulators of expression and function of LRP in Alzheimer's disease

The present invention broadly relates to the treatment, diagnosis, and prophylactic prevention of Alzheimer's disease. More specifically, the present invention relates to methods and compositions for preventing the endocytosis and cellular internalization of integral membrane amyloid .beta.-precursor protein (APP) and its subsequent catabolism by blocking or interfering with the association or binding of APP with members of the low density lipoprotein receptor family.

Growing community of inventors

Boston, MA, United States of America

Robert D Moir